Venous plasma levels of endothelin-1 are not altered immediately after nitroglycerin infusion in healthy subjects

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Venous plasma levels of endothelin-1 are not altered immediately after nitroglycerin infusion in healthy subjects. / Thomsen, L L; Iversen, Helle Klingenberg; Emmeluth, C; Bie, P.

In: European Journal of Clinical Pharmacology, Vol. 48, No. 2, 1995, p. 139-42.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Thomsen, LL, Iversen, HK, Emmeluth, C & Bie, P 1995, 'Venous plasma levels of endothelin-1 are not altered immediately after nitroglycerin infusion in healthy subjects', European Journal of Clinical Pharmacology, vol. 48, no. 2, pp. 139-42.

APA

Thomsen, L. L., Iversen, H. K., Emmeluth, C., & Bie, P. (1995). Venous plasma levels of endothelin-1 are not altered immediately after nitroglycerin infusion in healthy subjects. European Journal of Clinical Pharmacology, 48(2), 139-42.

Vancouver

Thomsen LL, Iversen HK, Emmeluth C, Bie P. Venous plasma levels of endothelin-1 are not altered immediately after nitroglycerin infusion in healthy subjects. European Journal of Clinical Pharmacology. 1995;48(2):139-42.

Author

Thomsen, L L ; Iversen, Helle Klingenberg ; Emmeluth, C ; Bie, P. / Venous plasma levels of endothelin-1 are not altered immediately after nitroglycerin infusion in healthy subjects. In: European Journal of Clinical Pharmacology. 1995 ; Vol. 48, No. 2. pp. 139-42.

Bibtex

@article{4e23f858b6d34419b5351b89350c976c,
title = "Venous plasma levels of endothelin-1 are not altered immediately after nitroglycerin infusion in healthy subjects",
abstract = "Endothelin-1 and nitric oxide play an important regulatory role in the control of vascular smooth muscle tone. Nitroglycerin (NTG), a nitric oxide donating drug, may inhibit endothelin production. In this double-blind placebo-controlled crossover study, plasma levels of endothelin-1 were measured before and immediately (5-30 s) after 80 min infusion of NTG (glyceryl trinitrate) or saline in 12 healthy subjects. On two different days separated by at least 1 week, NTG in four different doses, 0.015, 0.25, 1.0, and 2.0 micrograms. kg-1. min-1, or placebo (isotonic saline) was infused successively for 20 min each dose. During the infusion blood pressure and heart rate were measured. NTG infusion significantly decreased systolic blood pressure from 112.4 to 103.4 mmHg and pulse pressure from 39.3 to 29.5 mmHg. Heart rate increased from 62.7 to 73.1 beats. min-1. No changes in endothelin-1 plasma levels were induced by NTG infusion (2.4 pg.ml-1 before NTG vs. 2.7 pg.ml-1 after NTG) and placebo infusion also did not affect plasma endothelin-1. It is concluded that venous plasma levels of endothelin-1 are not altered immediately after NTG infusion.",
keywords = "Adult, Blood Pressure, Double-Blind Method, Endothelins, Female, Heart Rate, Humans, Injections, Intravenous, Male, Nitric Oxide, Nitroglycerin, Time Factors",
author = "Thomsen, {L L} and Iversen, {Helle Klingenberg} and C Emmeluth and P Bie",
year = "1995",
language = "English",
volume = "48",
pages = "139--42",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Venous plasma levels of endothelin-1 are not altered immediately after nitroglycerin infusion in healthy subjects

AU - Thomsen, L L

AU - Iversen, Helle Klingenberg

AU - Emmeluth, C

AU - Bie, P

PY - 1995

Y1 - 1995

N2 - Endothelin-1 and nitric oxide play an important regulatory role in the control of vascular smooth muscle tone. Nitroglycerin (NTG), a nitric oxide donating drug, may inhibit endothelin production. In this double-blind placebo-controlled crossover study, plasma levels of endothelin-1 were measured before and immediately (5-30 s) after 80 min infusion of NTG (glyceryl trinitrate) or saline in 12 healthy subjects. On two different days separated by at least 1 week, NTG in four different doses, 0.015, 0.25, 1.0, and 2.0 micrograms. kg-1. min-1, or placebo (isotonic saline) was infused successively for 20 min each dose. During the infusion blood pressure and heart rate were measured. NTG infusion significantly decreased systolic blood pressure from 112.4 to 103.4 mmHg and pulse pressure from 39.3 to 29.5 mmHg. Heart rate increased from 62.7 to 73.1 beats. min-1. No changes in endothelin-1 plasma levels were induced by NTG infusion (2.4 pg.ml-1 before NTG vs. 2.7 pg.ml-1 after NTG) and placebo infusion also did not affect plasma endothelin-1. It is concluded that venous plasma levels of endothelin-1 are not altered immediately after NTG infusion.

AB - Endothelin-1 and nitric oxide play an important regulatory role in the control of vascular smooth muscle tone. Nitroglycerin (NTG), a nitric oxide donating drug, may inhibit endothelin production. In this double-blind placebo-controlled crossover study, plasma levels of endothelin-1 were measured before and immediately (5-30 s) after 80 min infusion of NTG (glyceryl trinitrate) or saline in 12 healthy subjects. On two different days separated by at least 1 week, NTG in four different doses, 0.015, 0.25, 1.0, and 2.0 micrograms. kg-1. min-1, or placebo (isotonic saline) was infused successively for 20 min each dose. During the infusion blood pressure and heart rate were measured. NTG infusion significantly decreased systolic blood pressure from 112.4 to 103.4 mmHg and pulse pressure from 39.3 to 29.5 mmHg. Heart rate increased from 62.7 to 73.1 beats. min-1. No changes in endothelin-1 plasma levels were induced by NTG infusion (2.4 pg.ml-1 before NTG vs. 2.7 pg.ml-1 after NTG) and placebo infusion also did not affect plasma endothelin-1. It is concluded that venous plasma levels of endothelin-1 are not altered immediately after NTG infusion.

KW - Adult

KW - Blood Pressure

KW - Double-Blind Method

KW - Endothelins

KW - Female

KW - Heart Rate

KW - Humans

KW - Injections, Intravenous

KW - Male

KW - Nitric Oxide

KW - Nitroglycerin

KW - Time Factors

M3 - Journal article

C2 - 7589028

VL - 48

SP - 139

EP - 142

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 2

ER -

ID: 128984171